PMID- 34911421
OWN - NLM
STAT- MEDLINE
DCOM- 20211217
LR  - 20211217
IS  - 1875-5704 (Electronic)
IS  - 1567-2018 (Linking)
VI  - 18
IP  - 7
DP  - 2021
TI  - Characterization of Glyoxal Modified LDL: Role in the Generation of Circulating 
      Autoantibodies in Type 2 Diabetes Mellitus and Coronary Artery Disease.
PG  - 1027-1040
LID - 10.2174/1567201818666210810143548 [doi]
AB  - AIMS: This study aims to investigate the role of glyoxal modified LDL in the 
      immunopathology of diabetes and cardiovascular disease. BACKGROUND: Glycoxidation 
      of proteins is widely studied in relation to diabetes and cardiovascular disease. 
      OBJECTIVE: This study probed the glyoxal mediated modifications in LDL, analyzed 
      the immunogenicity of the glycated LDL and ascertained the presence of 
      circulating antibodies against modified LDL in patients with type 2 diabetes 
      mellitus (T2DM), coronary artery disease (CAD) and patients with both (T2DM+CAD). 
      METHODS: Glyoxal mediated modifications in LDL were studied by multiple 
      spectroscopic techniques, high-performance liquid chromatography and electron 
      microscopy. Immunization studies were carried in New Zealand rabbits. The 
      presence of antibodies against glyoxal modified LDL in immunized rabbits and 
      human subjects was analyzed by ELISA. RESULTS: Glyoxal altered the structural 
      integrity of LDL and led to the formation of AGEs. It decreased the alpha-helix 
      content of LDL; increased beta sheet formation, increased carbonyl content and 
      decreased free lysine and arginine content. Modified LDL showed aggregation, 
      generation of of Nepsilon- (Carboxymethyl) lysine and the formation of amorphous type 
      aggregates. It exhibited high antigenicity and generated a specific immune 
      response that shared common antigenic determinants with other glycated proteins. 
      Direct binding data showed the presence of anti-glyoxal modified LDL antibodies 
      in patients with T2DM, CAD and patients with both T2DM and CAD. Further analysis 
      in competitive binding assay revealed specific binding characteristics of 
      auto-antibodies. Sera from patients with T2DM+CAD exhibited the highest binding 
      with glyoxal modified LDL. CONCLUSION: Glyoxal-modified LDL has neo-antigenic 
      determinants that cause the generation of circulating antibodies in diabetes and 
      coronary artery disease. The study might have potential relevance in biomarker 
      development.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Rizwee, Md Masum
AU  - Rizwee MM
AD  - Department of Biochemistry, Jawaharlal Nehru Medical College, Faculty of 
      Medicine, Aligarh Muslim University, Aligarh, Uttar Pradesh, India.
FAU - Abidi, Minhal
AU  - Abidi M
AD  - Department of Biochemistry, Jawaharlal Nehru Medical College, Faculty of 
      Medicine, Aligarh Muslim University, Aligarh, Uttar Pradesh, India.
FAU - Habib, Safia
AU  - Habib S
AD  - Department of Biochemistry, Jawaharlal Nehru Medical College, Faculty of 
      Medicine, Aligarh Muslim University, Aligarh, Uttar Pradesh, India.
FAU - Mir, Abdul Rouf
AU  - Mir AR
AD  - Department of Biochemistry, Jawaharlal Nehru Medical College, Faculty of 
      Medicine, Aligarh Muslim University, Aligarh, Uttar Pradesh, India.
FAU - Ali, Asif
AU  - Ali A
AD  - Department of Biochemistry, Jawaharlal Nehru Medical College, Faculty of 
      Medicine, Aligarh Muslim University, Aligarh, Uttar Pradesh, India.
FAU - Uddin, Moin
AU  - Uddin M
AD  - Department of Biochemistry, Jawaharlal Nehru Medical College, Faculty of 
      Medicine, Aligarh Muslim University, Aligarh, Uttar Pradesh, India.
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Drug Deliv
JT  - Current drug delivery
JID - 101208455
RN  - 0 (Autoantibodies)
RN  - 0 (Epitopes)
RN  - 50NP6JJ975 (Glyoxal)
SB  - IM
MH  - Animals
MH  - Autoantibodies
MH  - *Coronary Artery Disease
MH  - *Diabetes Mellitus, Type 2
MH  - Epitopes
MH  - Glyoxal
MH  - Humans
MH  - Rabbits
OTO - NOTNLM
OT  - Glycation
OT  - Glyoxal
OT  - LDL
OT  - autoimmunity.
OT  - coronary artery disease
OT  - type 2 diabetes mellitus
EDAT- 2021/12/17 06:00
MHDA- 2021/12/18 06:00
CRDT- 2021/12/16 05:28
PHST- 2021/05/13 00:00 [received]
PHST- 2021/07/03 00:00 [revised]
PHST- 2021/07/03 00:00 [accepted]
PHST- 2021/12/16 05:28 [entrez]
PHST- 2021/12/17 06:00 [pubmed]
PHST- 2021/12/18 06:00 [medline]
AID - CDD-EPUB-117247 [pii]
AID - 10.2174/1567201818666210810143548 [doi]
PST - ppublish
SO  - Curr Drug Deliv. 2021;18(7):1027-1040. doi: 10.2174/1567201818666210810143548.